에피제네틱스 진단 시장 규모, 점유율, 동향 분석 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Epigenetics Diagnostics Market Size, Share & Trends Analysis Report By Product, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

에피제네틱스 진단 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 에피제네틱스 진단 시장은 2030년까지 391억 5,000만 달러에 달할 것으로 예측되며, 2025-2030년에 15.5%의 CAGR로 확대할 것으로 예측됩니다.

이러한 성장은 후성유전학 연구개발을 위한 투자, 자금 조달, 승인 증가 및 MDD(주요우울장애)의 유병률 증가에 기인합니다. 세계보건기구(WHO)에 따르면 2023년에는 성인의 약 5%가 우울장애를 경험할 것으로 예측됩니다. 또한 2022년 국립생물공학정보센터(NCBI)가 발표한 연구에 따르면 전 세계에서 약 2억 8,000만 명이 MDD를 앓고 있는 것으로 보고되고 있습니다. 신약개발과 신약개발에서 후성유전학의 적용이 확대되고 있으며, 유전체 염기서열 분석은 점점 더 저렴해지고 있습니다. 또한 후성유전학 신약개발과 관련된 기술의 발전도 이러한 성장에 기여하고 있습니다.

또한 후성유전학에 대한 공공 및 민간 기관의 투자 증가는 2023-2030년 시장 성장을 가속할 것으로 예상되며, 2025년 2월 TruDiagnostic은 DNA 메틸화, 장수 과학 및 진단 혁신을 연구하는 연구자들을 지원하기 위해 400만 달러의 보조금 지원 프로그램을 도입했습니다. 2022년 NCBI가 발표한 연구에 따르면 후성유전학적 변형은 세포 항상성과 유전체 유지에 중요한 역할을 하며, 바이러스 감염의 원인과 발달에 대한 정보를 제공한다는 연구 결과가 발표되었습니다.

후성유전체 진단 시장 : 분석 개요

• 2024년 제품별 점유율은 시약이 30.0% 이상을 차지할 것으로 예상되며, 이는 후성유전학 연구에서의 높은 사용률에 기인합니다.
• DNA 메틸화 부문은 2025-2030년의 예측 기간 중 44.5%의 연평균 복합 성장률(CAGR)로 가장 빠르게 성장할 것으로 예측됩니다.
• 2024년 시장 점유율은 암 분야가 최대로, 암 발병률 증가로 인해 에피제네틱스 시장은 예측 기간 중 성장할 것으로 전망됩니다.
• 학술연구 부문은 2024년 가장 큰 시장 점유율을 차지했습니다. 이러한 성장은 다양한 기업의 R&D에 대한 자금 지원 증가와 정부의 지원 구상 등의 요인에 기인합니다.
• 북미는 주요 기업의 존재와 첨단 의료 인프라로 인해 2024년 후성유전체 진단 시장을 선도했습니다. 또한 인지도 증가와 막대한 R&D 비용이 예측 기간 중 성장을 가속할 것으로 예측됩니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 에피제네틱스 진단 시장 : 변동 요인·경향·범위

• 시장 연관 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 에피제네틱스 진단 시장 : 분석 툴
  • 업계 분석 : Porter의 산업 분석
  • PESTEL 분석
• 에피제네틱스 진단 시장 : 파이프라인 분석

제4장 에피제네틱스 진단 시장 : 제품별 추정·동향 분석

• 제품별 대시보드
• 에피제네틱스 진단 시장 : 제품별 변동 분석
• 세계의 에피제네틱스 진단 시장 규모와 동향 분석 : 제품별(2018-2030년)
• 시약
• 키트
  • ChIP 시퀀싱 키트
  • 전게놈 증폭 키트
  • 중아황산염 변환 키트
  • RNA 시퀀싱 키트
  • 기타
• 장비
• 효소
• 서비스

제5장 에피제네틱스 진단 시장 : 기술별 추정·동향 분석

• 기술별 대시보드
• 에피제네틱스 진단 시장 : 기술별 변동 분석
• 에피제네틱스 진단 시장 규모와 동향 분석 : 기술별(2018-2030년)
• DNA 메틸화
  • 시약
  • 키트
  • 기기
  • 효소
  • 서비스
• 히스톤 메틸화
  • 시약
  • 키트
  • 기기
  • 효소
  • 서비스
• 히스톤 아세틸화
  • 시약
  • 키트
  • 기기
  • 효소
  • 서비스
• 장쇄 논코딩 RNA(lncRNA)
  • 시약
  • 키트
  • 기기
  • 효소
  • 서비스
• 마이크로 RNA 수식
  • 시약
  • 키트
  • 기기
  • 효소
  • 서비스
• 크로마틴 구조
  • 시약
  • 키트
  • 기기
  • 효소
  • 서비스

제6장 에피제네틱스 진단 시장 : 용도별 추정·동향 분석

• 용도별 대시보드
• 에피제네틱스 진단 시장 : 용도별 변동 분석
• 세계의 에피제네틱스 진단 시장 규모와 동향 분석 : 용도별(2018-2030년)
• 종양
  • 고형 종양
  • 액체 종양
• 종양 이외
  • 염증성 질환
  • 대사성 질환
  • 감염증
  • 심혈관질환
  • 기타

제7장 에피제네틱스 진단 시장 : 최종 용도별 추정·동향 분석

• 최종 용도별 대시보드
• 에피제네틱스 진단 시장 : 최종 용도별 변동 분석
• 세계의 에피제네틱스 진단 시장 규모와 동향 분석 : 최종 용도별(2018-2030년)
• 학술연구
• 임상 연구
• 병원·진료소
• 제약·바이오테크놀러지 기업
• 기타 사용자

제8장 에피제네틱스 진단 시장 : 지역별 추정·동향 분석

• 시장 대시보드 : 지역별
• 시장 점유율 분석 : 지역별(2024년·2030년)
• 에피제네틱스 진단 시장 : 주요 포인트, 지역별
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • 주요 기업의 히트맵 분석(2024년)
• 기업 개요
  • Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • Eisai Co. Ltd.
  • Novartis AG
  • Element Bisosciences, Inc.
  • Cantata Bio(Dovetail Genomics LLC.)
  • Illumina, Inc.
  • ValiRx Plc.
  • Abcam Ltd.

KSA

영문 목차

영문목차

Epigenetics Diagnostics Market Growth & Trends:

The global epigenetics diagnostics market is anticipated to reach USD 39.15 billion by 2030 and is anticipated to expand at a CAGR of 15.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to increased investment, funding, and approvals for epigenetics research and development, and the increasing prevalence of MDD (Major Depressive Disorder). According to the World Health Organization (WHO), in 2023, approximately 5% of adults experienced depressive disorders. Furthermore, a study published by the National Center for Biotechnology Information (NCBI) in 2022 reported that around 280 million people worldwide are affected by MDD. Epigenetics' applications in drug discovery and development are growing, and genome sequencing is becoming more affordable. Additionally, advancements in technology related to epigenetic drug discovery contribute to this growth.

Additionally, an increase in investment from both public and private organizations in epigenetics is expected to drive market growth from 2023 to 2030. In February 2025, TruDiagnostic introduced the grant, which provides USD 400,000 in funding to support researchers working in DNA methylation, longevity science, and diagnostic innovation. A study published by NCBI in 2022 stated that epigenetic modification plays a crucial role in maintaining cellular homeostasis and the genome and provides information about the cause and development of virus infection.

Epigenetics Diagnostics Market Report Highlights:

• Reagents dominated the product segment with more than 30.0% share in 2024, owing to their high usage in epigenetic research studies.
• The DNA Methylation segment is expected to grow at the fastest CAGR of 44.5% over the forecast period 2025 - 2030.
• The oncology segment held the largest market share in 2024, and with the increasing incidence of cancer, the epigenetic market is expected to grow over the forecast period.
• The academic research segment held the largest market share in 2024. The growth is attributed to the factors such as increased funding for research and development by various companies and supportive initiatives from the government.
• North America led the epigenetic diagnostics market in 2024 due to the presence of key market players and an advanced healthcare infrastructure. Additionally, increasing awareness along with significant R&D expenditure is expected to fuel growth throughout the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Technology
  • 2.2.3. Application
  • 2.2.4. End Use
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Epigenetics Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Epigenetics Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Epigenetics Diagnostics Market: Pipeline Analysis

Chapter 4. Epigenetics Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Epigenetics Diagnostics Market: Product Movement Analysis
• 4.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Reagents
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Kits
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. ChIP Sequencing Kit
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Whole Genomic Amplification kit
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Bisulfite Conversion kit
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. RNA Sequencing kit
    • 4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million
• 4.6. Instruments
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Services
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Epigenetics Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Epigenetics Diagnostics Market: Technology Movement Analysis
• 5.3. Epigenetics Diagnostics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. DNA Methylation
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Reagents
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Kits
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Instruments
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Enzymes
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Services
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Histone Methylation
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Reagents
    • 5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Kits
    • 5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Instruments
    • 5.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Enzymes
    • 5.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Services
    • 5.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Histone Acetylation
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Reagents
    • 5.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. Kits
    • 5.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Instruments
    • 5.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. Enzymes
    • 5.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Services
    • 5.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Large non - coding RNA
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Reagents
    • 5.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. Kits
    • 5.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Instruments
    • 5.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.5. Enzymes
    • 5.7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.6. Services
    • 5.7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. MicroRNA modification
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Reagents
    • 5.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.3. Kits
    • 5.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.4. Instruments
    • 5.8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.5. Enzymes
    • 5.8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.6. Services
    • 5.8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Chromatin structure
  • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.2. Reagents
    • 5.9.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.3. Kits
    • 5.9.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.4. Instruments
    • 5.9.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.5. Enzymes
    • 5.9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.6. Services
    • 5.9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Epigenetics Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Epigenetics Diagnostics Market: Application Movement Analysis
• 6.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Solid tumors
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Liquid tumors
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non - Oncology
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Inflammatory diseases
    • 6.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Metabolic diseases
    • 6.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Infectious diseases
    • 6.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Cardiovascular diseases
    • 6.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Others
    • 6.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Epigenetics Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Application Segment Dashboard
• 7.2. Epigenetics Diagnostics Market: End Use Movement Analysis
• 7.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Academic Research
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinical Research
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Hospitals & Clinics
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Pharmaceutical & Biotechnology Companies
  • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other Users
  • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Epigenetics Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. Continuous bioprocessing market by Region: Key Takeaways
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Denmark
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Norway
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework/ reimbursement structure
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company heat map analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Hoffmann- La Roche Ltd.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Thermo Fisher Scientific, Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Eisai Co. Ltd.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Novartis AG
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Element Bisosciences, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Cantata Bio (Dovetail Genomics LLC.)
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Illumina, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. ValiRx Plc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Abcam Ltd.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives

관련자료